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PATIENT SATISFACTION WITH PAIN MANAGEMENT 28 DAYS
AFTER TOTAL KNEE ARTHROPLASTY
Strassels SA1, Grossman P2, Blough DK1, Sullivan SD1, Colucci S2,
Richards P2, Strauss ME2
1University of Washington, Seattle, WA, USA; 2Purdue Pharma, LP,
Stamford, CT, USA
OBJECTIVES: Suboptimally treated postoperative pain is
common and is a risk factor for developing chronic pain. 
Additionally, improving postoperative pain relief may improve
patient-reported outcomes such as satisfaction with care. The
purpose of this study was to assess patient satisfaction with post-
operative pain relief among persons who underwent unilateral
total knee arthroplasty. METHODS: Participants in the intent-
to-treat population were randomly assigned to controlled-release
oxycodone (CRO, n = 125) or placebo (Pla, n = 119) plus usual
care on postoperative day two. Both groups were allowed sup-
plemental analgesics as needed. Outcomes assessed in this analy-
sis at baseline and overall were pain relief and impact of pain on
daily functions using the Brief Pain Inventory (BPI; an objective
pain outcome measure) and two items related to satisfaction with
postoperative pain care, speciﬁcally, “How satisﬁed or dissatis-
ﬁed are you with the relief you experienced from your post-
surgery pain?” and “Overall how pleased have you been with
the current care you have received for post-surgery pain?”
RESULTS: Patients on CRO compared to Pla reported greater
perceived amount of pain relief from study medications (p =
0.007), with satisfaction of current care (p = 0.069) trending
towards signiﬁcance. In addition, 85.8% (CRO) and 72.0% (Pla;
p = 0.033) would recommend the care they received, including
pain management. Questions about satisfaction with pain man-
agement were positively and signiﬁcantly associated with the
Brief Pain Inventory pain relief item (r = 0.47 and 0.38, respec-
tively). CONCLUSIONS: Patients who received CRO were more
satisﬁed with their pain relief and were more likely to recom-
mend their pain care to someone else.
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SELECTED OUTCOMES IN PATIENTS WITH OVERACTIVE
BLADDER COMPARED TO NON-OVERACTIVE BLADDER
CONTROLS
Daniel G1, Kamat SA1, Brewer K1, Bullano MF1,Telly T2,
Williamson T2
1HealthCore, Inc, Wilmington, DE, USA; 2Yamanouchi Pharma
America, Inc, Paramus, NJ, USA
OBJECTIVE: This was a retrospective claims study in a managed
care population. Selected outcomes were compared in newly-
diagnosed overactive bladder (OAB) cases and controls.
METHODS: Insurance claims data from a southeastern US
health plan totaling approximately 4.4 million members were
utilized. All patients were ≥18 years of age and had continuous
insurance eligibility for one year pre- and ≥1 year post-
enrollment date. The two year enrollment period for OAB
patients was between January 1, 2001 and December 31, 2002.
Newly-diagnosed OAB patients had ≥2 medical visits related to
OAB on separate dates during the enrollment period but not a
medical visit related to OAB in the one year pre-enrollment
period. Non-OAB controls had no medical visit related to OAB
over the period of continuous eligibility. Cases were matched to
controls utilizing a propensity score approach. All medical and
pharmacy insurance encounter data (claims) were collected for
one year pre-enrollment and ≥1 year post-enrollment for both
groups. RESULTS: Among OAB cases, 1087/4640 (23%)
received ≥1 OAB drug over the observation period; 93% dis-
continued treatment. Median treatment duration was 30 days.
Compared to non-OAB controls, OAB cases were signiﬁcantly
associated with: skin infections at rates 57% higher, urinary tract
infection (UTI) at rates 3.6 times higher, and new onset depres-
sion at rates 55% higher. CONCLUSION: Patients with OAB
were associated with higher rates of skin infection, UTI, and
new-onset depression compared to non-OAB cases. Evaluation
of effect of OAB treatment on these events was not feasible given
the low median treatment time. These events are likely to have
great quality of life impact as well as signiﬁcant health care
resource use, including outpatient visits and pharmacological
intervention.
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THE COST-EFFECTIVENESS OF SUBSTITUTING
DARBAPOETIN FOR EPOETIN:WHEN ECONOMIC
MODELLING DOES NOT PREDICT REAL LIFE RESULTS
Basskin LE
North Shore Medical Center, Cooper City, FL, USA
OBJECTIVES: To determine if costs savings from a substitution
of darpapoetin for epoetin were as predicted by an economic
model. METHODS: Our hospital, part of a National purchas-
ing consortium, was convinced to switch all patients receiving
either thrice weekly or weekly epoeitin, in connection with either
chemotherapy of chronic renal disease, to once weekly dar-
bapoeitin. An economic model showed that under the assump-
tions provided, combined with a 22% rebate of cost from the
manufacturer, that total costs would be lower with darbapoetin.
Clinical literature was reviewed showing similar efﬁcacy of the
two agents. RESULTS: After implementing the switch, the costs
of making the subsitution were much higher than the beneﬁts.
Use and acquisition costs of darbapoetin was signiﬁcantly greater
than the prior year and then were predicted using the economic
model. Signiﬁcant ﬁndings were; a) demonstrated lack of clini-
cal equivalence lead to physicians prescribing 2.8 times the rec-
ommended dose of darbapoetin and; b) paying for a week’s
worth of therapy for patients who would only have received an
average of 1.3 doses of epoeitin based on their duration of stay
in the hospital. A revised model based on more realistic assump-
tions showed a net cost would result if the substitution were con-
tinued. CONCLUSION: Despite the results predicted by the
economic model, without restrictions on the amount of drug to
be ordered, the total costs to our health care system turned out
to be much greater after the substitution.
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OBJECTIVE: Successful treatment of overactive bladder (OAB)
reduces the occurrence of OAB symptoms and associated condi-
tions and may reduce total health care costs. The objective of
this study was to compare treatment discontinuation and one-
year health care costs for OAB patients starting treatment with
extended-release tolterodine (TOL) versus extended-release oxy-
butynin (OXY). METHODS: A cost-minimization model was
developed from the payer perspective. A cohort of OAB patients
newly treated with TOL (n = 15,394) or OXY (n = 7934) was
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selected using the PharMetrics Patient-Centric Database. All
patients were assumed to be on original therapy for the ﬁrst
month, with discontinuation rates derived from the subsequent
11-month period. Medical costs were estimated based on payer
reimbursements for all services rendered to TOL and OXY
patients matched for demographic and pretreatment clinical
characteristics. Subsequent costs for those who discontinued
therapy were based on patients receiving medical management
without drug therapy (n = 29,992). Costs for drugs were pro-
vided by AnalySource (October 2004). RESULTS: After the 
11-month follow-up period, 21% of TOL and 15% of OXY
patients remained on original therapy. Mean total health care
costs per patient were $8876/y for those originally on TOL and
$9080/y for those started on OXY. Sensitivity analyses indicated
that results were robust to changes in drug cost and probability
of discontinuation. When persistence was held equal, cost dif-
ferences continued to favor TOL: 21% = $272/year and 15% =
$233/year. Furthermore, for the model to result in equivalent
annual health care costs, TOL cost must increase by $1.50/day
or OXY cost must decrease by $1.62/day. CONCLUSIONS: At
the end of one year, OAB patients were more likely to remain on
original treatment taking TOL versus OXY. This resulted in a
total health care cost savings of $204 per patient.
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A COMPARISON OF TOTAL DIRECT MEDICAL COSTS AMONG
PATIENTS RECEIVING AGENTS USED IN THE
PHARMACOLOGIC MANAGEMENT OF OVERACTIVE
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OBJECTIVE: We compared the direct health care costs for
patients receiving different prescription pharmacologic agents
for overactive bladder (OAB) symptoms in a managed care
setting. METHODS: We used administrative medical and phar-
macy claims data from >30 managed care plans. Patients newly
diagnosed with OAB who initiated treatment with tolterodine
extended release (TOL ER), oxybutynin extended release (OXY
ER), or oxybutynin immediate release (OXY IR) were followed
for 12 months from the date of initial diagnosis. Patients were
required to be continuously eligible for pharmacy and medical
beneﬁts during the study period. Total mean medical costs 
were assessed for the 12-month follow-up period and were com-
pared across the treatment groups after statistical adjustment for
age, sex, and days to treatment initiation. Medical costs were
calculated from inpatient admissions, emergency room visits,
outpatient physician visits, other prescription drugs, and diag-
nostic/laboratory services. RESULTS: A total of 6110 patients
initiated treatment with TOL ER (mean age 55y, 77% women),
3325 with OXY ER (mean age 55y, 73% women), and 893 with
OXY IR (mean age 57y, 61% women). Patients who received
OXY ER ($9063) and OXY IR ($10,523) had signiﬁcantly
higher adjusted annual mean medical costs than did patients who
received TOL ER ($8073, p = 0.0175 and p = 0.0001, respec-
tively). CONCLUSIONS: Diagnosing and managing patients
with OAB is challenging, especially as it relates to pharmacologic
treatment. Observed lower medical costs of TOL ER patients in
this study may have broad implications. Results from this study
warrant further analysis that fully incorporates adjustments for
the factors associated with treatment selection as well as disease-
speciﬁc drivers of health care costs.
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ECONOMIC EVALUATION OF EVEROLIMUS WITH REDUCED-
DOSE CYCLOSPORINE IN DE NOVO RENAL TRANSPLANT
RECIPIENTS: AN INTERNATIONAL PERSPECTIVE
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OBJECTIVE: To assess the economic impact of everolimus 1.5
mg with reduced-dose cyclosporine (CsA) vs. mycophenolate
moteﬁl (MMF2g) with full dose CsA in de novo renal transplant
recipients. METHODS: A previous trial (B201) which prospec-
tively collected resource utilization during one-year showed
similar economic outcomes for everolimus vs. MMF2g with 
full-dose CsA. Direct medical costs (excluding everolimus, 
CsA and MMF) were mostly dependent on key clinical events:
hemodialysis, length of stay (LOS) due to adverse events (AE) 
or infection (INF), biopsy proven acute rejection (BPAR) and
days on cytomegalovirus (CMV) therapy. A subsequent trial of
everolimus with reduced-dose CsA demonstrated similar efﬁcacy
(A2306). A multivariate model was ﬁtted on the B201 data to
predict direct medical costs. Coefﬁcients were then applied to the
A2306 data to predict the economic outcomes of everolimus
with reduced-dose CsA. As no signiﬁcant country-speciﬁc cost
effect on LOS was found, individual country cost vectors were
applied (Germany, France and Spain). RESULTS: For Germany,
incremental costs were 250€ per hemodialysis session (p <
0.001), 261€ per day of hospitalization due to AE (p < 0.001),
343€ per day of hospitalization due to INF (p < 0.001) and
4473€ per BPAR (p < 0.001). After adjusting for recipient age,
living donors, and CMV therapy between B201 and A2306,
everolimus with reduced-dose CsA decreased 1-year costs by
3260€ vs. MMF with full-dose CsA. Taking into account cost 
of CsA, MMF and everolimus (assuming parity pricing of
everolimus 1.5mg and MMF 2g), everolimus with reduced-dose
CsA decreased total 1-year costs in Germany by 3960€. In Spain
and France, the ﬁnal cost-savings would be 1516€ and 3217€,
respectively. CONCLUSION: In de novo kidney transplant
recipients over a 1-year follow-up period, everolimus 1.5mg 
with reduced-dose CsA is a cost-saving strategy compared to
MMF-based regimen. Further analyses in other health care set-
tings are needed to fully document the cost-saving of everolimus
1.5mg.
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A PHARMACOECONOMIC EVALUATION OF OXYBUTYNIN
AND TOLTERODINE FOR THE TREATMENT OF OVERACTIVE
BLADDER
Ko Y, Malone DC,Armstrong EP
University of Arizona,Tucson, AZ, USA
OBJECTIVES: To develop a decision analytic model comparing
the cost-effectiveness of various preparations of oxybutynin 
and tolterodine in the treatment of overactive bladder (OAB).
METHODS: The model included immediate-release oxybutynin
(OxyIR), extended-release oxybutynin (OxyER), transdermal
oxybutynin (OxyTD), immediate-release tolterodine (TolIR),
and extended-release tolterodine (TolER). Treatment success was
deﬁned as complete continence (no incontinence episodes). The
model was constructed from the payer’s perspective, assuming
incontinence pads were a covered beneﬁt. The timeframe for the
model was three months. Costs included were medications,
incontinence pads, and treatment of OAB-induced morbidities
(i.e., urinary tract infections, fractures, depression, and skin
infections). The selection of clinical outcomes data was based on
the following priority: 1) FDA approval label; 2) randomized
